Global Hemophilia Market Size & Trends Report Segmented by Disease Type (Hemophilia A, B, C), Therapy (Factor Replacement, Non-Factor Replacement, Gene Therapy, Immune Tolerance Induction Therapy), End User & Regional Forecast to 2031

Research Methodology

The study has been compiled based on extensive primary and secondary research.

Secondary Research (Indicative List)

Primary Research

To validate research findings (market size & forecasts, market segmentation, market dynamics, competitive landscape, key industry trends, etc.), extensive primary interviews were conducted with both supply and demand-side stakeholders.

Supply Side Stakeholders:

• Senior Management Level: CEOs, Presidents, Vice-Presidents, Directors, Chief Technology Officers, Chief Commercial Officers

• Mid-Management Level: Product Managers, Sales Managers, Brand Managers, R&D Managers, Business Development Managers, Consultants

Demand Side Stakeholders:

• Hospitals and Specialized Clinics, Academics and Research Centres, and others

Breakdown of Primary Interviews
 

Market Size Estimation

Both ‘Top-Down & Bottom-Up Approaches’ were used to derive market size estimates and forecasts

Data Triangulation

Research findings derived through secondary sources & internal analysis was validated with Primary Interviews, Internal Knowledge Repository and Company’s Sales Data